Last reviewed · How we verify
clobetasol propionate + Methotrexate
Clobetasol propionate is a topical corticosteroid that reduces inflammation, while methotrexate is an immunosuppressant that inhibits cell growth and division.
Clobetasol propionate is a topical corticosteroid that reduces inflammation, while methotrexate is an immunosuppressant that inhibits cell growth and division. Used for Severe plaque psoriasis, Severe atopic dermatitis.
At a glance
| Generic name | clobetasol propionate + Methotrexate |
|---|---|
| Sponsor | University Hospital, Montpellier |
| Drug class | Corticosteroid and immunosuppressant |
| Modality | Small molecule |
| Therapeutic area | Dermatology and Autoimmune Disorders |
| Phase | Phase 3 |
Mechanism of action
Clobetasol propionate works by binding to glucocorticoid receptors, which then inhibit the production of pro-inflammatory cytokines. Methotrexate, on the other hand, inhibits dihydrofolate reductase, leading to a decrease in DNA synthesis and cell proliferation.
Approved indications
- Severe plaque psoriasis
- Severe atopic dermatitis
Common side effects
- Skin atrophy
- Hypersensitivity reactions
- Gastrointestinal disturbances
Key clinical trials
- Topical 1% Methotrexate Gel Versus Clobetasol Propionate in Patients With Psoriasis (EARLY_PHASE1)
- Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients (PHASE3)
- Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: